neurotrophic receptor tyrosine kinase 1
آخر تحديث 18 Aug 2020
يتوافق مع الإرشادات التحريرية
- تنزيلتنزيل
- مشاركة
- Language
- نقاش
- Ask Patient
- نسخة صوتية
- أضف إلى المصادر المفضلة على جوجل
ال NTRK1 gene provides instructions for making a protein that is essential for the development and survival of nerve cells (neurons), especially those that transmit information about sensations such as pain, temperature, and touch (sensory neurons). The NTRK1 protein is found on the surface of cells, particularly sensory neurons. It acts as a kinase, which is an enzyme that changes the activity of other proteins by adding a cluster of oxygen and phosphorus atoms (a phosphate group) at specific positions. This process is called phosphorylation. The NTRK1 protein is turned on (activated) when another protein called nerve growth factor beta (NGFβ) attaches (binds) to it and signals the NTRK1 protein to phosphorylate itself (autophosphorylation). Then, the activated NTRK1 protein phosphorylates other proteins; this process is needed to transmit signals for cell growth and survival.
اختيارات الفيديو لـ Genesمكتبة الفيديو
Normal function
ال NTRK1 gene provides instructions for making a protein that is essential for the development and survival of nerve cells (neurons), especially those that transmit information about sensations such as pain, temperature, and touch (sensory neurons). The NTRK1 protein is found on the surface of cells, particularly sensory neurons. It acts as a kinase, which is an enzyme that changes the activity of other proteins by adding a cluster of oxygen and phosphorus atoms (a phosphate group) at specific positions. This process is called phosphorylation. The NTRK1 protein is turned on (activated) when another protein called nerve growth factor beta (NGFβ) attaches (binds) to it and signals the NTRK1 protein to phosphorylate itself (autophosphorylation). Then, the activated NTRK1 protein phosphorylates other proteins; this process is needed to transmit signals for cell growth and survival.
Conditions referring to this gene or chromosome
Other names
high affinity nerve growth factor receptor
MTC
neurotrophic tyrosine kinase, receptor, type 1
NTRK1_HUMAN
p140-TrkA
TRK
Trk-A
TRK1
TRK1-transforming tyrosine kinase protein
TRKA
tyrosine kinase receptor A
Related patient information and medicines

Patient information leaflet
سرطان الفم
Epidermal growth factor receptor monoclonal antibody (EGFR mAb) is one form of targeted therapy. Cetuximab is an EGFR mAb. Tyrosine kinase inhibitors (TKIs) are another. Immunotherapy is treatment that aims to boost the body's own immune system to destroy the cancer cells. It is also sometimes called biological therapy: Recombinant interleukin.

Patient information leaflet
ابيضاض الدم النقوي المزمن
Treatment for the initial chronic phase The aim of treatment is to control the disease process, to ease any symptoms and to prevent (or delay) the progress... You may be advised to have one or more of the following treatments: Imatinib tablets. This medicine is known as a tyrosine kinase inhibitor. The chemical tyrosine kinase is made by the.

Patient information leaflet
داء الخلايا البدينة واضطرابات الخلايا البدينة
If the condition is severe, surgery to remove the spleen (splenectomy), medicines that have an effect on ... Dr Sarah Jarvis , 28th September 2021 Midostaurin for treating advanced systemic mastocytosis The National Institute for Health and Care Excellence (NICE) has brought out new guidance on the use of midostaurin for people with mastocytosis..

Patient information leaflet
دواء الغثيان
Ondansetron is also sometimes used to treat nausea and vomiting from gastroenteritis Gastroenteritis. Aprepitant Aprepitant to prevent sickness and fosaprepitant - these are newer medicines and work by blocking a chemical that acts on neurokinin receptors in the body to cause nausea. They are sometimes called neurokinin-1 receptor antagonists..

Patient information leaflet
هل يمكنني تناول ألوجليبتين وريبيلسوس معًا؟
Taking alogliptin and Rybelsus (semaglutide) together can significantly increase the risk of your blood sugar dropping too low (hypoglycaemia). Additionally, both medicines work in a similar way on the same hormonal pathway, and using them together is generally not recommended because it does not provide extra benefit but increases the....

Patient information leaflet
الوهن العضلي الوبيل
Myasthenia gravis (MG) is a condition where muscles become easily tired and weak. It is due to a problem with how the nerves stimulate the muscles to tighten (contract). The muscles become easily tired and weak. What causes myasthenia gravis. الوهن العضلي الوبيل هو an autoimmune disease. This means that the immune system The immune system (which.
قراءة إضافية ومراجع
- neurotrophic receptor tyrosine kinase 1; MedlinePlus, National Library of Medicine.
- Greco A, Miranda C, Pierotti MA. Rearrangements of NTRK1 gene in papillary thyroid carcinoma. Mol Cell Endocrinol. 2010 May 28;321(1):44-9. doi: 10.1016/j.mce.2009.10.009. Epub 2009 Oct 31.
- Indo Y, Tsuruta M, Hayashida Y, Karim MA, Ohta K, Kawano T, Mitsubuchi H, Tonoki H, Awaya Y, Matsuda I. Mutations in the TRKA/NGF receptor gene in patients with congenital insensitivity to pain with anhidrosis. Nat Genet. 1996 Aug;13(4):485-8. doi: 10.1038/ng0896-485.
- Indo Y. Molecular basis of congenital insensitivity to pain with anhidrosis (CIPA): mutations and polymorphisms in TRKA (NTRK1) gene encoding the receptor tyrosine kinase for nerve growth factor. Hum Mutat. 2001 Dec;18(6):462-71. doi: 10.1002/humu.1224.
- Kaplan DR, Miller FD. Neurotrophin signal transduction in the nervous system. Curr Opin Neurobiol. 2000 Jun;10(3):381-91. doi: 10.1016/s0959-4388(00)00092-1.
- Miranda C, Di Virgilio M, Selleri S, Zanotti G, Pagliardini S, Pierotti MA, Greco A. Novel pathogenic mechanisms of congenital insensitivity to pain with anhidrosis genetic disorder unveiled by functional analysis of neurotrophic tyrosine receptor kinase type 1/nerve growth factor receptor mutations. J Biol Chem. 2002 Feb 22;277(8):6455-62. doi: 10.1074/jbc.M110016200. Epub 2001 Nov 21.
- Pierotti MA, Greco A. Oncogenic rearrangements of the NTRK1/NGF receptor. Cancer Lett. 2006 Jan 28;232(1):90-8. doi: 10.1016/j.canlet.2005.07.043. Epub 2005 Oct 20.
- Verpoorten N, De Jonghe P, Timmerman V. Disease mechanisms in hereditary sensory and autonomic neuropathies. Neurobiol Dis. 2006 Feb;21(2):247-55. doi: 10.1016/j.nbd.2005.08.004. Epub 2005 Sep 23.
تاريخ المقال
المقال متاح أيضًا باللغة الإنجليزية, الألمانية, إسبانية, الفرنسية, إيطالي, البرتغالية, الهندية, العبرية, العربية ,، و السويدية.
18 Aug 2020 | أحدث إصدار
1 May 2011 | نُشر في الأصل
شارك أفكارك أو تجاربك مع الآخرين في مجتمعات المرضى.
اشترك في النشرة الإخبارية للمرضى
جرعتك الأسبوعية من النصائح الصحية الواضحة والموثوقة - مكتوبة لمساعدتك على الشعور بالاطلاع والثقة والتحكم.
من خلال الاشتراك، فإنك تقبل سياسة الخصوصية. يمكنك إلغاء الاشتراك في أي وقت. نحن لا نبيع بياناتك أبدًا.

